Hepatocellular carcinoma remains a substantial global public health concern, disproportionately affecting low-income and middle-income countries, particularly in Africa.1 Its burden in Africa is ...

KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 ...

Clinical trial patient recruitment and retention practices have significantly advanced over the last 15 years thanks to ...

First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025; UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of Euro ...

A large new study will follow the health and well-being of thousands of transgender and gender nonconforming young people in the UK.

RESEARCHERS have found that an artificial intelligence model combining data from wearable glucose monitors, gut microbiome ...

KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 ...

Fecal microbiota transplantation in long-term care patients shows safety and potential to lower infection rates, despite ...

If we've got vaccines for so many other viruses - including Covid-19, which emerged only a few years ago - why don't we have ...

A Mediterranean diet during pregnancy significantly alters the maternal gut microbiome, increasing beneficial bacteria, while ...

Inclusion isn’t just about eligibility; it’s about participation Trials often demand time, travel and flexibility, resources ...

Society of Urologic Oncology Award: Jianhua Xiong, PhD, will receive support for a two-year research project titled “Lipid ...